Eton Pharmaceuticals Submits New Drug Application for Topiramate Oral Solution

Eton Pharmaceuticals Submits New Drug Application for Topiramate Oral Solution
0
(0)

Eton Pharmaceuticals has submitted a new drug application (NDA) for topiramate oral solution — an anticonvulsant formerly known as ET-101 — to the U.S. Food and Drug Administration (FDA).

The NDA covers three indications: as an add-on therapy for treatment of partial-onset seizures, including those associated with Lennox-Gastaut syndrome (LGS) in patients 2 and older; as a single therapy for partial-onset or primary general tonic-clonic seizures in patients 2 and older; and as preventative migraine treatment in patients 12 and older.

“Topiramate is one of the most widely compounded oral liquids, and our product addresses the unmet need for pediatric-friendly formulations of the molecule. We look forward to working with the FDA to bring a safe, effective, FDA-approved product to patients and caregivers as quickly as possible,”  Sean Brynjelsen, Eton’s CEO, said in a press release.

FDA approval would make topiramate oral solution the first approved liquid formulation of the medicine. Topiramate, an anticonvulsant that is used to treat seizures in adults and children and to prevent migraines in adults and adolescents, is currently available only as tablets and capsules.

The company expects the liquid formulation to enable more precise dosing than the solid forms allow. It also addresses challenges related to dysphagia (difficulty swallowing), which often makes taking solid medication difficult for patients.

A bioequivalence study in healthy male volunteers had shown topiramate oral solution to be equivalent (functionally identical) to solid forms of of the medicine, when taken under fasting conditions. A food effect study further indicated that food did not diminish liquid topiramate’s effect or its bioavailability (the extent to which a medicine reaches its intended destination in the body).

ET-101 is Eton’s third neurology-focused liquid product candidate to be submitted to the FDA. The other two also address seizures: zonisamide oral suspension (ET-104), for those associated with epilepsy; and lamotrigine oral suspension (ET-105), for partial seizures, primary generalized tonic-clonic seizures, and generalized seizures of LGS in patients 2 and older.

Eton anticipates the approval and launch of all three of neurology product candidates in 2021.

Lennox-Gastaut syndrome is a severe form of epilepsy with few effective treatment options. It often features co-occurring conditions, including learning disabilities, mobility problems, and developmental delays.

 

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.
Total Posts: 0
Ana de Barros, PhD Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.
×
Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.
Latest Posts
  • Topiramate Oral Solution
  • Topiramate Oral Solution

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *